MGLL and metabolic dysfunction-associated steatohepatitis: Through comprehensive in vitro and in vivo analyses, we demonstrate that AKBA effectively reduces hepatic lipid accumulation and inflammation via direct interaction with monoacylglycerol lipase (MGLL), suggesting that AKBA may represent a promising, side-effect-free therapeutic candidate for the treatment of NASH.